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Abstract
Background. Sevelamer carbonate is an improved,
bufferedformofsevelamerhydrochloridedevelopedforthe
treatment of hyperphosphataemia in CKD patients. Seve-
lamercarbonateformulatedasapowderfororalsuspension
presents a novel, patient-friendly alternative to tablet phos-
phate binders. This study compared the safety and efficacy
of sevelamer carbonate powder with sevelamer hydrochlo-
ride tablets in CKD patients on haemodialysis.
Methods. This was a multi-centre, open-label, random-
ized, crossover design study. Thirty-one haemodialysis pa-
tientswererandomlyassignedtoeithersevelamercarbonate
powder or sevelamer hydrochloride tablets for 4 weeks fol-
lowed by a crossover to the other regimen for an additional
4 weeks.
Results. The mean serum phosphorus was 1.6 ±
0.5 mmol/L (5.0 ± 1.5 mg/dL) during sevelamer carbonate
powder treatment and 1.7 ± 0.4 mmol/L (5.2 ± 1.1 mg/dL)
duringsevelamerhydrochloridetablettreatment.Sevelamer
carbonate powder and sevelamer hydrochloride tablets are
equivalent in controlling serum phosphorus; the geometric
least square mean ratio was 0.95 (90% CI 0.87–1.03). No
statistically significant or clinically meaningful differences
were observed in calcium × phosphorus product and lipid
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levels between sevelamer carbonate powder and sevelamer
hydrochloride tablets. Serum bicarbonate levels increased
2.7 ± 3.7 mmol/L (2.7 ± 3.7 mEq/L) during sevelamer
carbonate treatment. No statistically significant change in
bicarbonate was observed during sevelamer hydrochloride
treatment. Sevelamer carbonate powder and sevelamer hy-
drochloride were well tolerated during this study.
Conclusions. Sevelamer carbonate powder and seve-
lamer hydrochloride tablets are equivalent in controlling
serum phosphorus and well tolerated in CKD patients on
haemodialysis. Bicarbonate levels improved only during
sevelamer carbonate treatment. Sevelamer carbonate pow-
dershouldprovideawelcomednewoptionforthetreatment
of hyperphosphataemia for CKD patients on dialysis.
Keywords: clinical trial; haemodialysis patients; phosphate binder;
powder formulation; sevelamer carbonate
Introduction
Chronic kidney disease (CKD) patients as a whole and
dialysis patients in particular have a high intake of medi-
cations. Dialysis patients typically take >13 different types
of medication and >40 tablets a day. Studies suggest that
patients fail to take 18–20% or more of their prescribed
phosphate binders [1]. The overall pill burden for dialysis
patients may be a substantial element contributing to poor
compliance with medications. Large pill burden has specif-
ically been cited as one cause for patients’ poor adherence
tophosphatebinder[1,2].Powderformofphosphatebinder
would provide choice to patients in how their binder is de-
livered and be useful for patients seeking to decrease the
number of tablets they take.
It is not just the number of tablets that creates problems
for dialysis patients, but difficulty in swallowing tablets
or capsules may also contribute to poor compliance in
some patients. In a survey of 792 patients conducted by
community pharmacists, ∼60% of the patients reported ex-
periencing difficulties swallowing solid dosage forms and
69% admitted skipping a dose of medication due to swal-
lowing difficulties [3]. In another survey, approximately
one-quarter (26%) of >6000 patients seen by general prac-
titioners reported problems in swallowing tablets [4]. The
size,textureandtastewerethemostfrequentcomplaintsde-
scribed in this survey. Age-related physiological changes,
including age-related declines in salivary gland function
and swallowing reflexes, may contribute to swallowing dif-
ficulties. Medical conditions such as Parkinson’s disease,
stroke and cancer can also lead to swallowing difficulties.
Manyphosphatebindersareonlyavailableinasoliddosage
form, and the nature of phosphate binding requires that
several tablets a day will have to be taken. An alternative
powder dosage form that can be suspended in water may
benefit patients who dislike or have difficulty using solid
dosage forms of medications.
Sevelamer hydrochloride (Renagel
R  
) is a non-absorbed,
calcium- and metal-free phosphate-binding polymer that
has been available since 1998. Sevelamer hydrochloride ef-
fectively controls serum phosphorous and calcium × phos-
phorus product while maintaining normal serum calcium
levels in haemodialysis patients when dosed three times
per day [5–10]. However, treatment with sevelamer hy-
drochloride may be associated with an increase in serum
chloride and/or reduction in serum bicarbonate and the po-
tential to aggravate the metabolic acidosis frequently ex-
perienced by CKD patients [11,12]. The chloride anion of
sevelamer hydrochloride may contribute to these effects.
Therefore, sevelamer carbonate (Renvela
R  
) was developed
as a buffered form of sevelamer. Sevelamer carbonate is an
anion-exchange resin with the same polymeric structure as
sevelamer hydrochloride where carbonate is an alternative
counterion to chloride. While the counterions differ for the
two salts, the polymer itself, the active moiety responsi-
ble for the binding of phosphate, is the same. Sevelamer
carbonate contains bicarbonate and carbonate equivalent to
0.14–0.21gofbicarbonatepergramofsevelamercarbonate
active pharmaceutical ingredient.
Sevelamer carbonate tablets have been found to be well-
tolerated and equivalent to sevelamer hydrochloride tablets
in controlling serum phosphorus in haemodialysis patients
[13]. In addition to the tablet formulation, sevelamer car-
bonate has also been designed specifically as a powder
formulation for aqueous suspension to provide more op-
tions to patients. Sevelamer carbonate powder has a light
citrus flavour. Dosing instructions recommend mixing at
least 60 mL of water with each 2.4 g of powder. Even when
taken three times per day, this amount of water should not
negatively impact patients whose fluid intake is restricted.
The current study was designed to compare the safety
andefficacyofsevelamercarbonatepowderwithsevelamer
hydrochloride tablets in CKD patients on haemodialysis.
Methods
Patient selection
Patients aged ≥18 years receiving maintenance haemodialysis for
3 months or longer at seven nephrology centres in England who were
maintainedonsevelamerhydrochloridealoneorincombinationwithother
binders formed the candidate population. Laboratory criteria for inclusion
included aserumphosphoruslevel≥1.76mmol/L(5.5 mg/dL) after phos-
phatebinderwashout,anintactparathyroidhormone(iPTH)measurement
of ≤800 ng/L (800 pg/mL) and a serum calcium level within the normal
range[2.13–2.58mmol/L(8.5–10.3mg/dL)].Patientswereexcludedfrom
thestudyiftheyhadaseveregastrointestinalmotilitydisorder,poorlycon-
trolled diabetes mellitus, hypertension or any other clinically significant
unstable medical condition.
The protocol and informed consent were reviewed and approved by
an Independent Ethics Committee. All patients signed written, informed
consent prior to the initiation of any study-related activities. This research
was carried out in accordance with Good Clinical Practice guidelines,
applicable regulations as well as the ethical principles that have their
origin in the Declaration of Helsinki.
Study design
This was a multi-centre, open-label, randomized, crossover design study.
Patients were screened, and enrolled patients discontinued all phosphate
binder(s)fora2-weekwashoutperiod.Attheendofthewashoutperiod,the
patients with a serum phosphorus ≥1.76 mmol/L (5.5 mg/dL) continued
into a 4-week sevelamer hydrochloride run-in period. The binder dose that
each patient was taking prior to the washout period was replaced with an
equivalentnumberof 800mgsevelamer hydrochloridetablets. Therewere
two opportunities during the run-in period to adjust the dose of sevelamer
hydrochloride, if necessary, to keep serum phosphorus levels within a
target level between 1.12 and 1.76 mmol/L (3.5 and 5.5 mg/dL), inclusive.3796 S. Fan et al.
Following the run-in period, the patients were randomized in a 1:1 fashion
to one of two treatment sequences: sevelamer carbonate powder dosed
TID with meals for 4 weeks followed by sevelamer hydrochloride tablets
dosed TID with meals for 4 weeks or sevelamer hydrochloride tablets
dosed TID with meals for four weeks followed by sevelamer carbonate
powder dosed TID with meals for 4 weeks. The dose was individualized
based on the patients’ most recent sevelamer hydrochloride dose during
the run-in period. The patients were maintained at a fixed dose throughout
bothtreatmentperiods.Thepatients’haemodialysisprescriptionregarding
dialysatebicarbonate,calciumconcentrationsandtreatmenttimewastobe
maintained throughout both treatment regimens. Adherence was assessed
by pill or sachet count twice during each treatment period. At the end
of the second treatment period, study medication was discontinued and
the patients were instructed to return to their pre-study phosphate-binder
medication. The patients returned for a follow-up visit after 7 days.
Efficacy and safety analyses
The effects of sevelamer carbonate powder and sevelamer hydrochloride
tablets, each dosed TID with meals, on the control of serum phosphorus
was determined using equivalence testing. The natural log-transformed
time-weighted average of the serum phosphorus assessments from the
last four visits during the last 2 weeks of each treatment regimen were
used in the analysis. The time-weighted average of the serum phosphorus
assessments during the last 2 weeks of each treatment regimen was used
to give a more accurate assessment of phosphorus control than would be
attained by individual measurements. The analysis of variance (ANOVA)
model included a random subject effect and fixed sequence, period and
treatmenteffects.Thetwoone-sidedhypothesesweretestedatthe5%level
of significance for log-transformed serum phosphorus by constructing a
90% confidence interval for the ratio of sevelamer carbonate to sevelamer
hydrochloridegeometricmeans.Thistestrequiredthatthe90%confidence
interval for the ratio was within the interval (0.80, 1.25) to establish
equivalence. Similar ANOVA models were used to compare calcium ×
phosphorusproductandlipidsbetweentreatmentregimensatthe5%level.
Percent compliance and average actual daily dose were summarized by
treatment regimen. Safety was evaluated on the basis of adverse experi-
ences and changes in laboratory values.
Allowing for withdrawals, a sample size of 12 patients per sequence
(powder/tabletversustablet/powder)foratotalof24patientswasrequired
to be randomized to achieve 90% power to detect equivalence.
Results
Patients
A total of 75 individual patients were enrolled in this study
to randomize 31 patients (17 to the sevelamer carbonate
powder/sevelamer hydrochloride tablet sequence and 14
to the sevelamer hydrochloride tablet/sevelamer carbon-
ate powder sequence). Seven patients discontinued dur-
ing sevelamer carbonate treatment (two due to adverse
events and five withdrew consent). A total of 24 (77.4%)
completed the study (14 in the sevelamer carbonate pow-
der/sevelamer hydrochloride tablet sequence and 10 in the
sevelamer hydrochloride tablet/sevelamer carbonate pow-
der sequence).
The patient demographics and renal history are shown in
Table 1. Overall, the baseline characteristics of the patients
were similar between treatment sequences.
The equivalence analysis was based on a comparison of
serum phosphorus control using the per protocol set (PPS;
n=21)asthisistheappropriatepopulationforequivalence
testing. Confirmatory analyses of serum phosphorus and
the analyses of the secondary endpoints, calcium × phos-
phorus product and lipids were performed using the intent
to treat (ITT) population (n = 30). Safety was assessed in
Table 1. Patient demographics and renal history
Characteristic (N = 31)
Age (years)
Mean ± SD 52.9 ± 13.2
Median (range) 51 (27–80)
Gender, n (%)
Male 21 (68)
Female 10 (32)
Ethnicity, n (%)
Caucasian 22 (71)
Black 3 (10)
Asian 6 (19)
Primary cause of end-stage renal disease, n (%)
Othera 18 (58)
Glomerulonephritis 8 (26)
Diabetes 4 (13)
Hypertension 1 (3)
Time on dialysis (years)
Mean ± SD 7.2 ± 8.0
Median (range) 4.4 (0.2–30.3)
Pre-study phosphate binder, n (%)
Sevelamer hydrochloride 18 (58)
Sevelamer hydrochloride and calcium 11 (36)
Other 2 (7)
Using IV or oral vitamin D, n (%) 25 (81)
Kidney transplant prior to study, n (%) 8 (26)
Parathyroidectomy prior to study, n (%) 4 (13)
aOf the 18 patients with ‘other’ cited as the primary cause, the aetiology
of CKD was recorded as unknown in five patients, IgA nephropathy in
two patients, polycystic kidneys in two patients and interstitial nephritis,
pyelonephritis, congenital, renovascular disease, reflux nephropathy, road
traffic accident, hereditary nephritis, Goodpasture syndrome and Alport’s
syndrome in one patient each.
all patients who received at least one dose of randomized
study medication (n = 31).
Study treatment exposure
In the PPS, the mean actual daily dose was 6.0 ± 3.1 g/
day of sevelamer carbonate powder and 6.4 ± 3.3 g/day
of sevelamer hydrochloride tablets. No patients changed
their sevelamer daily dose during randomized treatment.
Treatmentcompliancewassimilarwithbothsevelamercar-
bonate powder (86%) and sevelamer hydrochloride tablets
(84%).
Efficacy
The mean time-weighted average serum phosphorus was
1.6 ± 0.5 mmol/L (5.0 ± 1.5 mg/dL) during sevelamer
carbonate powder treatment and 1.7 ± 0.4 mmol/L (5.2 ±
1.1 mg/dL) during sevelamer hydrochloride tablet treat-
ment. For assessing phosphorus equivalence, the treatment
response across sequences was pooled since there was no
sequence effect (P = 0.932). The geometric least square
mean ratio (sevelamer carbonate powder/sevelamer hy-
drochloride tablets) was 0.95 with a corresponding 90%
confidence interval of 0.87–1.03. The confidence inter-
val is within the interval of 0.80–1.25, indicating that
sevelamer carbonate powder and sevelamer hydrochloride
tablets are equivalent in controlling serum phosphorus. The
results of a confirmatory analysis conducted with the ITTPhosphorus control with sevelamer carbonate powder 3797
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Fig. 1. Serum phosphorus over time.
population corroborate the PPS analysis. The mean serum
phosphorusateachstudyvisitispresentedinFigure1.This
figure demonstrates that similar serum phosphorus control
wasattainedduringtreatmentwithsevelamercarbonateand
sevelamer hydrochloride throughout the study.
Table 2 presents the calcium × phosphorus product and
lipid results. No statistically significant or clinically mean-
ingful differences were observed in calcium × phosphorus
product and lipid levels between sevelamer carbonate pow-
der and sevelamer hydrochloride tablets dosed TID with
meals.
The serum bicarbonate, calcium and iPTH over time are
presented in Table 3. During sevelamer carbonate pow-
der treatment, there was a statistically significant increase
fromtheendoftherun-inperiod(baseline)totheendofthe
treatmentperiod(final)inserumbicarbonate[meanchange
2.7 mmol/L (2.7 mEq/L) from 18.0 mmol/L (18.0 mEq/L);
P = 0.001]. No statistically significant change in bicar-
bonate was observed during sevelamer hydrochloride treat-
ment.Theobservedchangeinserumbicarbonatewasstatis-
tically significantly different between treatment regimens,
with greater increases in the sevelamer carbonate regimen
(P = 0.001). There was no statistically significant change
in serum calcium (albumin-adjusted) during either treat-
ment, and no statistically significant difference in calcium
(albumin-adjusted)changebetweenthetreatmentregimens.
TherewasnostatisticallysignificantdifferenceintheiPTH
change between the treatment regimens.
Safety
Sevelamer carbonate powder and sevelamer hydrochloride
were well tolerated during this study. A total of nine events
in7(22.6%)ofthe31randomizedpatientswereconsidered
bytheinvestigatorastreatmentrelatedduringthesevelamer
hydrochloride run-in period including dyspepsia, abdomi-
nal distension, abdominal pain, diarrhoea, gastritis, nau-
sea and stomach discomfort. No treatment-related adverse
events were reported during treatment with sevelamer hy-
drochloridetabletsduringtherandomizedtreatmentperiod.
Four adverse events in three (9.7%) patients (nausea and
vomiting in one patient, nausea in one patient and consti-
pation in one patient) that occurred during sevelamer car-
bonate treatment were assessed as treatment related. The
two patients who experienced nausea and vomiting with-
drew from the study due to these events. No serious AEs
were considered to be related to either study treatment by
the investigator. No patients died during either treatment
period.
Discussion
In this study, sevelamer carbonate powder and seve-
lamer hydrochloride tablets, both dosed TID with meals,
were equivalent in controlling serum phosphorus in CKD
Table 2. End of treatment serum calcium × phosphorus product and lipids
Laboratory parameter Sevelamer carbonate powder TID Sevelamer hydrochloride tablets TID P-value
Calcium × phosphorus product 0.749
(mmol2/L2) (mg2/dL2)
n 25 28
Mean ± SD 3.7 ± 1.1 (45.9 ± 13.8) 3.7 ± 0.8 (45.8 ± 10.0)
Median 3.8 (46.6) 3.8 (46.9)
Total cholesterol (mmol/L) (mg/dL) 0.218
n 22 27
Mean ± SD 3.5 ± 0.7 (135.4 ± 26.9) 3.3 ± 0.8 (129.1 ± 31.6)
Median 132 (3.4) 127 (3.3)
LDL cholesterol (mmol/L) (mg/dL) 0.109
n 22 27
Mean ± SD 1.8 ± 0.5 (70.4 ± 18.3) 1.8 ± 0.7 (67.7 ± 25.4)
Median 67 (1.7) 65 (1.7)
HDL cholesterol (mmol/L) (mg/dL) 0.537
n 22 27
Mean ± SD 1.2 ± 0.5 (44.5 ± 17.7) 1.1 ± 0.4 (43.7 ± 13.9)
Median 43 (1.1) 42 (1.1)
Triglycerides (mmol/L) (mg/dL) 0.992
n 22 27
Mean ± SD 2.2 ± 1.6 (192.7 ± 139.6) 2.1 ± 1.5 (188.9 ± 131.9)
Median 144 (1.6) 142 (1.6)3798 S. Fan et al.
Table 3. Laboratory measurements over time
Laboratory parameter Sevelamer carbonate powder TID (N = 31) Sevelamer hydrochloride tablets TID (N = 28) P-value∗
Bicarbonate (mmol/L) (mEq/L) 0.001
Baseline 18.0 ± 3.1 (18.0 ± 3.1) 17.8 ± 3.2 (17.8 ± 3.2)
Final 20.2 ± 2.8 (20.2 ± 2.8) 18.0 ± 3.1 (18.0 ± 3.1)
Change 2.7 ± 3.7 (2.7 ± 3.7) 0.1 ± 3.3 (0.1 ± 3.3)
P-value∗ 0.001 0.791
Calcium (mmol/L) (mg/dL) 0.665
Baseline 2.3 ± 0.2 (9.1 ± 0.9) 2.3 ± 0.2 (9.1 ± 1.0)
Final 2.3 ± 0.2 (9.1 ± 0.8) 2.3 ± 0.2 (9.1 ± 0.9)
Change −0.0 ± 0.1 (−0.1 ± 0.5) −0.0 ± 0.2 (−0.0 ± 0.9)
P-value∗ 0.173 0.734
iPTH (pmol/L) (pg/mL)a 0.404
Baseline 31 (291) 33 (310)
Final 41 (390) 43 (408)
Change 3 (30) 4 (42)
P-value∗ 0.272 0.019
aSerum iPTH presented as median.
∗Wilcoxonsigned-ranktestusedtocomparechangefrombaselinebetweentreatmentregimensandtoassesschangefrombaselinewithineachtreatment.
The number of observations varies in the statistics shown.
patients on haemodialysis. Sevelamer carbonate powder
was well tolerated by the patients in this study. The safety
profile of sevelamer carbonate powder was similar to the
known safety profile of sevelamer carbonate tablets and
sevelamer hydrochloride tablets. These findings are par-
ticularly supportive of sevelamer carbonate as an effective
phosphatebindersincedespitechangesinboththeformula-
tion (tablet to powder) and the counterion (hydrochloride to
carbonate), equivalent phosphorus control with sevelamer
hydrochloride was demonstrated.
Sevelamer carbonate for oral suspension may be particu-
larly beneficial for several patient populations. Elderly and
other patients who have difficulty in taking solid dosage
forms of medications may find a suspension easier to
swallow. The patients who are overwhelmed by the num-
ber of pills that they must take each day may find an oral
suspension preferable. A powder formulation for oral sus-
pension may also provide a more suitable formulation than
tablets for paediatric patients. Thus, the availability of an
oral suspension provides the patient with a dosage option
that could result in increased compliance with therapy that
could improve patient outcomes. The similar compliance
rates for the powder and tablet formulations seen in this
study may be related to this being a well-controlled clinical
trial of short duration and likely does not accurately reflect
long-term compliance with each formulation.
Reducedserumbicarbonatelevels(<22mmol/L)arefre-
quently observed in CKD patients indicating that many of
the patients have an underlying acidosis [14]. Acidosis has
been associated with adverse effects on bone metabolism
[15] and increased malnutrition and inflammation [14] in
haemodialysispatients.Inaddition,metabolicacidosiswith
a serum bicarbonate level of <17.5 mmol/L has been in-
dependently associated with an increased risk of death in
dialysis patients [16,17]. In this study, bicarbonate levels
increased during sevelamer carbonate treatment. The addi-
tion of the buffering capacity provided by sevelamer car-
bonate could potentially decrease the burden of acidosis in
CKD patients. It may also decrease the need for additional
sodium bicarbonate tablet supplementation, potentially re-
ducing the pill burden for some patients.
Sevelamer carbonate powder and sevelamer hydrochlo-
ride were well tolerated during this study. The nature and
severity of adverse events was consistent with the adminis-
trationofphosphatebinderstopatientswithCKDreceiving
dialysis.Treatment-relatedadverseeventsduringsevelamer
carbonate were gastrointestinal in nature, which is consis-
tent with the occurrence of related adverse events during
the sevelamer hydrochloride run-in period and the product
labelling.
Although these results are very encouraging, the study
was limited by a design that was open label and did
not include a washout period between the active treat-
ment periods. The study was open label due to the prac-
tical considerations involved in blinding patients to study
medication assignment (powder versus tablet). The use of
a double-dummy approach would have required patients
to have a considerable study medication burden, which
may have caused patients to be non-compliant and could
thereby compromise the validity of the study. No washout
period occurred between treatment periods, as carryover
effects were not expected at the time of efficacy mea-
surements. This was supported by the lack of a sequence
effect.
In summary, this study demonstrated that sevelamer car-
bonate powder was a well-tolerated, effective phosphate
binder that was equivalent to sevelamer hydrochloride
tablets in controlling serum phosphorus in CKD patients
onhaemodialysis.Sevelamercarbonatepowdershouldpro-
videawelcomednewoptionforthetreatmentofhyperphos-
phataemia for CKD patients.
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Abstract
Background. There is growing evidence of the usefulness
of vitamin D supplementation in dialysis patients who are
most often vitamin D deficient. Due to the long half-life
of vitamin D, there is much interest in administering it
intermittently for long-term adherence. However, there are
no data to indicate which dosage would be most efficient.
Objective. The aim was to assess the long-term effi-
ciency and safety of a monthly oral dose of cholecalciferol
(100 000 IU) in vitamin D-deficient haemodialysis (HD)
patients.
Methods. HD patients with a serum 25-hydroxyvitamin D
(25(OH)D) level <75 nmol/L were enrolled in a 15-month
prospective study. The exclusion criteria were as follows:
use of any vitamin D derivatives, prescription of cinacal-
cet and bisphosphonates, uncontrolled hypercalcaemia
(>2.55 mmol/L), hyperphosphataemia (>2 mmol/L) and
severe secondary hyperparathyroidism (SHPT; serum
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